Intra-Cellular Therapies IncChange company Symbol lookupSelect an option...ITCI Intra-Cellular Therapies IncHUN Huntsman CorpIART Integra Lifesciences Holdings CorpR Ryder System IncAAPL Apple IncIIM Invesco Value Municipal Income TrustQQQ Invesco QQQ TrustVZ Verizon Communications IncCHTR Charter Communications IncSPB Spectrum Brands Holdings IncGo
Intra-Cellular Therapies, Inc. is a biopharmaceutical company. The Company is focused on the discovery, clinical development and commercialization of small molecule drugs that address underserved medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS). The Company provides CAPLYTA (lumateperone) for the treatment of schizophrenia in adults. The CAPLYTA is a prescription medicine used to treat the depressive episodes in adults with bipolar I or II, that can be taken alone or with lithium or valproate. The Company's pipeline is focused on three platforms: lumateperone and follow-on compounds, a phosphodiesterase 1 (PDE1) inhibitor platform and discovery platform which includes ITI-333 a novel compound with high affinity at serotonin 5-HT2A, dopamine D1 and mu opioid (MOP) receptors. The Company’s subsidiaries are ITI, Inc. (ITI) and ITI Limited.
|
|
|
|
| |
ITCI's position in the Pharmaceuticals industry
| Industry Peers | LLY | |
|---|---|---|
Summary | ||
| Company Profile | Intra-Cellular Therapies, Inc. is a biopharmaceutical company. The Company is focused on the discovery, clinical development and commercialization of small molecule drugs that address underserved... | Eli Lilly and Company is a drug manufacturing company. The Company is engaged in the discovery, development, manufacturing, marketing, and sales of pharmaceutical products across the world. The... Go to LLY summary |
| 52-Week Change | VS. INDUSTRY | 16.93% |
| Market Cap | VS. INDUSTRY | $289.4B |
| Beta | VS. INDUSTRY | 0.3 |
| Dividend Yield | VS. INDUSTRY | 1.29% |
| P/E (TTM, GAAP) | VS. INDUSTRY | 48.61x |
| Data as of | ||
Fundamentals | ||
| Total Revenue (TTM) | VS. INDUSTRY | $29.1B |
| Profit Margin | VS. INDUSTRY | 19.58% |
| Earnings Growth (5 year, GAAP) | VS. INDUSTRY | 18.88% |
| Revenue Growth (TTM) | VS. INDUSTRY | 8.77% |
| Data as of |
Copyright © 2022. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.